MK-677 / Ibutamoren

Published · Researched 2026-09-21

NOT A PEPTIDE. MK-677 (ibutamoren) is an orally active non-peptide small-molecule ghrelin mimetic. It is included here because it is the single most-discussed growth-hormone secretagogue in peptide communities, and every "peptides vs MK-677" debate in the dataset runs through it.

Overview

Developed by Merck in the 1990s (developmental codes MK-0677 / L-163,191), ibutamoren is a spiropiperidine-class agonist of the ghrelin / growth-hormone secretagogue receptor (GHS-R1a). It stimulates endogenous pulsatile GH release and raises IGF-1 with once-daily oral dosing — no injections. Merck discontinued development; the compound was later licensed to Lumos Pharma as LUM-201, which ran Phase 2 (OraGrowtH212) and planned Phase 3 trials for moderate pediatric GH deficiency (PGHD). Lumos was taken private in December 2024 (per company disclosures); current program status in 2026 is not confirmed in today's sources — UNVERIFIED. In the gray market it is sold as capsules, tablets, and oral liquids.

Social standing

The most-discussed oral GH compound across the entire social dataset (60 dedicated entries in the extraction):

• Instagram: dominant. A Hindi-language creator's "Mk 677 - my experience" testimonial (Feb 2026 reel) reported overwhelming hunger (~5,000 kcal days), 10–12 hour sleepiness, and water retention after 3 days — comments split between "where to buy / DM bro, genuine brands only" purchase inquiries and debate over whether the experience was exaggerated. A comedic reel (Sep 2025) warns "don't take mk677 guys it made me go fucking crazy and get really gassy and fat" — performative but reflects the real complaint cluster (gas, fat gain). HNR Labs Recovery's educational reel positions it as "sustains your GH around the clock — one daily dose keeps GH steadily elevated," with commenters warning about appetite, diabetes/insulin-resistance risk, edema, and joint problems alongside copy-paste supplier spam ("99.9% purity and COA"). Fitness creator Alexander Diago (@diagofitreal) promotes 20 mg as a "cheat code for mass" (extreme hunger, deeper sleep, rapid scale weight) — comments split between skeptics reporting minimal effects and others warning of long-term harm. A "THE FIT EXECUTIVE" infographic compares MK-677 vs "MK-777 (next generation)": half-life ~24 h vs ~8–10 h, appetite and glucose/insulin impact contrasted — MK-677 framed as established but with hunger, water retention, and reduced insulin sensitivity as drawbacks.
• Threads: active Q&A layer — timing debates (morning vs bedtime dosing; one creator notes studies used morning dosing but he prefers evening), height-growth questions from younger users.
• Facebook: reels present (e.g., "MK-677 Full review" explainer); Groups show purchase-intent traffic. FB Marketplace: zero listings observed 2026-09-20.
• Main praise: oral convenience (no injections), appetite (for hard gainers), deeper sleep, steady GH elevation.
• Main complaints: uncontrollable hunger/fat gain, lethargy/sleepiness, water retention/edema, gas, insulin-resistance and diabetes-risk warnings, heavy supplier spam polluting every discussion.

Short attributed quotes: "sustains your GH around the clock" (HNR Labs reel caption); "DM bro, genuine brands only" (recurring comment reply — illustrates the spam layer, not an endorsement).

Social validation — Tier 1

Key specs table

Pricing

• MSRP: none — no approved product.
• Research-chem / gray-market street: capsules/tablets/liquids widely listed by research-chem vendors; 2026 price points not collected in this batch — UNVERIFIED. (Typical community-cited range is tens of dollars per month supply — UNVERIFIED.)
• Compounded/clinic: not a compounded-therapy item.
• Facebook Marketplace range: no listings observed 2026-09-20.

What's included / what's needed

Gray-market: bottles of capsules/tablets or oral solution/suspension with dropper; no reconstitution needed (oral). No pharma patient packaging exists.

Support reality

No pharma support for gray-market use. Vendor COA culture (purity claims, frequently copy-pasted as comment spam). The legitimate clinical program (Lumos LUM-201) is a pharma track with no consumer channel.

Regulatory & safety status

Research chemical not for human use. Never FDA- or EMA-approved for any indication. WADA-prohibited at all times (S2 — listed alongside the GHRPs). Safety signals: community and literature converge on increased appetite/weight gain, edema/fluid retention, transient insulin resistance and blood-glucose elevation (diabetes-risk warnings are pervasive in comments), lethargy, and gas/bloating. Literature-reported: a Phase 2b trial in elderly subjects was terminated on DSMB recommendation over a congestive-heart-failure safety signal (Adunsky et al. 2011 — as cited in prior research summaries; exact current citation not re-verified today, treat detail as UNVERIFIED). Lumos Phase 2 pediatric data reported the main risk as increased appetite with general tolerability. No long-term safety data for chronic gray-market use.

Community verdict

MK-677 is the peptide scene's oral shortcut: unmatched discussion volume, genuine appeal (no needles, real appetite and sleep effects), and the worst signal-to-noise ratio in the category — every thread is part testimonial, part diabetes warning, part supplier spam. The community treats it as effective but blunt, with the insulin-resistance question as the unresolved shadow over long-term use.

Image log

• hero: present — mk-677-ibutamoren-hero.jpg (observation 2026-09-20)
• side: present — mk-677-ibutamoren-side.jpg
• rear: present — mk-677-ibutamoren-rear.jpg
• detail: present — mk-677-ibutamoren-detail.jpg
• box: present — mk-677-ibutamoren-box.jpg
• top: MISSING — no distinct top-view image located
• inuse: MISSING — no real owner in-use photo located
• scale: MISSING — no scale-reference photo located

All images: curl HEAD/GET-checked, magic-verified, JPEG, observation 2026-09-20. Zero AI-generated.

Open questions / UNVERIFIED

• Exact literature half-life figure (community infographic says ~24 h; not re-verified against PK literature).
• Current Lumos Pharma LUM-201 Phase 3 status in 2026 (company taken private Dec 2024).
• Adunsky 2011 CHF-signal citation details (not re-verified today).
• Gray-market price points (not collected).
• Whether chronic use causes durable insulin resistance vs transient shifts (community's central open debate).

Not medical advice. This file is research documentation only; nothing here is a recommendation to use any compound.

Named sources

• @diagofitreal — Fitness creator Alexander Diago (@diagofitreal) promotes 20 mg as a "cheat code for mass" (extreme hunger, deeper sleep, rapid scale weight) — comments split between skeptics reporting minimal effects and others warning of long-term harm.
• MK-677 Full review — reels present (e.g., "MK-677 Full review" explainer); Groups show purchase-intent traffic.
• Instagram — dominant. (Feb 2026)
• Threads — active Q&A layer — timing debates (morning vs bedtime dosing; one creator notes studies used morning dosing but he prefers evening), height-growth questions from younger users.
• Facebook — reels present (e.g., "MK-677 Full review" explainer); Groups show purchase-intent traffic. (2026-09-20)
• Threads Q&A (2025–2026) — Proves active user timing/dosing debates and youth height-growth interest (2025–2026)
• Facebook reels + Groups (2026) — Proves purchase-intent traffic and review-style content (2026)
• Lumos Pharma disclosures / ENDO 2024 posters (via web) — Proves legitimate clinical program (LUM-201) exists — separates pharma track from gray-market use (2024)

Source URLs were not recorded for these references.